Lunai Bioworks Inc. Stock-Based Compensation
Lunai Bioworks Inc. (LNAI) reported Stock-Based Compensation of $168.99 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-05-15
- Lunai Bioworks Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $168.99K, a 88.73% decline year-over-year.
- Lunai Bioworks Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $128.82K, a 76.94% decline year-over-year.
- Lunai Bioworks Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $181.31K, a 49.30% decline year-over-year.
- Lunai Bioworks Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was $897.81K.
- Lunai Bioworks Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $3.31M, a 29.10% decline from fiscal 2024.
- Lunai Bioworks Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $4.67M, a 32.19% increase from fiscal 2023.
- Lunai Bioworks Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $3.54M, a 32.51% decline from fiscal 2022.
- Lunai Bioworks Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $5.24M, a 303.63% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | $168.99K 10-Q · filed 2026-05-15 | $297.81K derived: sum of 2 quarters · filed 2026-05-15 | $479.12K 10-Q · filed 2026-05-15 | $1.38M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2025-12-31 | $128.82K 10-Q · filed 2026-05-15 | $310.13K derived: sum of 2 quarters · filed 2026-05-15 | $1.21M derived: sum of 3 quarters · filed 2026-05-15 | $2.71M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2025-09-30 | $181.31K 10-Q · filed 2026-05-15 | $1.08M derived: sum of 2 quarters · filed 2026-05-15 | $2.58M derived: sum of 3 quarters · filed 2026-05-15 | $3.14M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2025-06-30 | $897.81K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $2.40M derived: sum of 2 quarters · filed 2026-05-15 | $2.96M derived: sum of 3 quarters · filed 2026-05-15 | $3.31M 10-K · filed 2025-09-29 | ||
| 2025-03-31 | $1.50M 10-Q · filed 2026-05-15 | $2.06M derived: sum of 2 quarters · filed 2026-05-15 | $2.42M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $558.63K 10-Q · filed 2026-05-15 | $916.28K 10-Q · filed 2025-02-19 | ||||
| 2024-09-30 | $357.65K 10-Q · filed 2026-05-15 | |||||
| 2024-06-30 | $4.67M 10-K · filed 2025-09-29 | |||||
| 2024-03-31 | $1.86M 10-Q · filed 2025-05-15 | $2.86M derived: sum of 2 quarters · filed 2025-05-15 | $3.84M derived: sum of 3 quarters · filed 2025-05-15 | $4.46M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $999.23K 10-Q · filed 2025-05-15 | $1.98M 10-Q · filed 2025-02-19 | $2.60M derived: sum of 3 quarters · filed 2025-05-15 | $3.56M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-09-30 | $983.83K 10-Q · filed 2025-05-15 | $1.60M derived: sum of 2 quarters · filed 2025-05-15 | $2.56M derived: sum of 3 quarters · filed 2025-05-15 | $3.38M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-06-30 | $612.88K derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-02-19 | $1.58M derived: sum of 2 quarters · filed 2025-02-19 | $2.40M derived: sum of 3 quarters · filed 2025-02-19 | $3.54M 10-K/A · filed 2025-02-19 | ||
| 2023-03-31 | $968.20K 10-Q/A · filed 2025-02-19 | $1.08M 10-Q · filed 2023-05-12 | $1.79M derived: sum of 2 quarters · filed 2025-02-19 | $2.92M 10-Q · filed 2023-05-12 | $2.70M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2022-12-31 | $819.96K 10-Q/A · filed 2025-02-19 | $1.85M 10-Q · filed 2023-03-09 | $1.74M derived: sum of 3 quarters · filed 2025-02-19 | $2.31M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2022-09-30 | $1.03M 10-Q/A · filed 2025-02-19 | $915.32K derived: sum of 2 quarters · filed 2025-02-19 | $1.49M derived: sum of 3 quarters · filed 2025-02-19 | $3.54M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2022-06-30 | -$110.69K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-02 | $466.99K derived: sum of 2 quarters · filed 2023-10-02 | $2.51M derived: sum of 3 quarters · filed 2023-10-02 | $5.24M 10-K · filed 2023-10-02 | ||
| 2022-03-31 | $577.68K 10-Q · filed 2023-05-12 | $2.62M derived: sum of 2 quarters · filed 2023-05-12 | $5.35M 10-Q · filed 2023-05-12 | $5.46M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $2.04M 10-Q · filed 2023-03-09 | $4.77M 10-Q · filed 2023-03-09 | $4.88M derived: sum of 3 quarters · filed 2023-03-09 | $5.38M derived: sum of 4 quarters · filed 2023-03-09 | ||
| 2021-09-30 | $2.73M 10-Q · filed 2023-03-07 | $2.84M derived: sum of 2 quarters · filed 2023-03-07 | $3.34M derived: sum of 3 quarters · filed 2023-03-07 | $3.70M derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2021-06-30 | $112.82K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $612.25K derived: sum of 2 quarters · filed 2023-02-27 | $971.64K derived: sum of 3 quarters · filed 2023-02-27 | $1.30M 10-K · filed 2023-02-27 | ||
| 2021-03-31 | $499.43K 10-Q · filed 2022-05-13 | $858.82K derived: sum of 2 quarters · filed 2022-05-13 | $1.18M 10-Q · filed 2022-05-13 | $1.17M derived: sum of 4 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $359.39K 10-Q · filed 2022-02-14 | $668.48K 10-Q · filed 2022-02-14 | $685.55K 10-Q · filed 2021-02-16 | $674.29K derived: sum of 3 quarters · filed 2022-02-14 | $646.20K derived: sum of 4 quarters · filed 2022-02-14 | |
| 2020-09-30 | $326.16K 10-Q · filed 2021-11-15 | $314.90K derived: sum of 2 quarters · filed 2021-11-15 | $286.81K derived: sum of 3 quarters · filed 2021-11-15 | $976.87K derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | -$11.25K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | -$39.35K derived: sum of 2 quarters · filed 2021-09-24 | $650.71K derived: sum of 3 quarters · filed 2021-09-24 | $884.72K 10-K · filed 2021-09-24 | ||
| 2020-03-31 | -$28.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-17 | $661.97K derived: sum of 2 quarters · filed 2021-05-17 | $895.98K 10-Q · filed 2021-05-17 | $1.06M derived: sum of 4 quarters · filed 2021-05-17 | ||
| 2019-12-31 | $690.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-16 | $924.07K 10-Q · filed 2021-02-16 | $1.09M derived: sum of 3 quarters · filed 2021-02-16 | $1.18M derived: sum of 4 quarters · filed 2021-02-16 | ||
| 2019-09-30 | $234.01K 10-Q · filed 2020-11-12 | $396.02K derived: sum of 2 quarters · filed 2020-11-12 | $492.75K derived: sum of 3 quarters · filed 2020-11-12 | $2.27M derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $162.01K derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-23 | $258.74K derived: sum of 2 quarters · filed 2020-09-23 | $2.04M derived: sum of 3 quarters · filed 2020-09-23 | $2.12M 10-K · filed 2020-09-23 | ||
| 2019-03-31 | $96.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-11 | $1.88M derived: sum of 2 quarters · filed 2020-05-11 | $1.96M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-10 | $1.87M 10-Q · filed 2020-02-10 | ||||
| 2018-09-30 | $86.17K 10-Q · filed 2019-11-13 | |||||
| 2018-06-30 | $63.72K 10-K · filed 2019-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |